CSF3 and Decreased total neutrophil count: A total of 177 (15%) patients received G-CSF after their first episode of G3-4 neutropenia; 128 (23%) in the FOLFOXIRI/bevacizumab arm and 49 (8%) in the doublets/bevacizumab arm.